Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 3/20 | 0.49 |
| ▸ | MEN1 | O00255 | 4/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.47 |
| ▸ | NPC1 | O15118 | 3/20 | 0.47 |
| ▸ | RAB9A | P51151 | 3/20 | 0.47 |
| ▸ | HTT | P42858 | 3/20 | 0.47 |
| ▸ | RAPGEF3 | O95398 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.43 |
| ▸ | CASP3 | P42574 | 1/20 | 0.43 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7379752 | 0.86 | TSHR (0.54) | TSHRKDM4ELMNAMEN1KMT2A | |
| SCHEMBL7379755 | 0.86 | TSHR (0.54) | TSHRKDM4ELMNAMEN1KMT2A | |
| SCHEMBL1879882 | 0.80 | L3MBTL1 (0.42) | MEN1KMT2ASMN1; SMN2RAPGEF3MAPT | |
| SCHEMBL1405492 | 0.80 | RAPGEF3 (0.43) | KDM4ESMN1; SMN2RAPGEF3MAPT | |
| SCHEMBL4276791 | 0.79 | TSHR (0.51) | TSHRKDM4ELMNAMEN1KMT2A | |
| SCHEMBL4276786 | 0.79 | TSHR (0.51) | TSHRKDM4ELMNAMEN1KMT2A | |
| SCHEMBL7088222 | 0.78 | ALDH1A1 (0.43) | TSHRKDM4EMEN1KMT2AMAPT | |
| SCHEMBL1405519 | 0.77 | GAA (0.40) | TSHRKDM4EMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL22647634 | 0.76 | MAPT (0.48) | TSHRKDM4ELMNASMN1; SMN2RAB9A | |
| SCHEMBL11061164 | 0.74 | MAPT (0.64) | TSHRKDM4ELMNAMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7935674-B2 | Indole derivatives | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-05-03 | — | — | US | disclosed |
| CN-101111492-B | Indole derivatives | TANABE SEIYAKU CO | 2010-09-22 | — | — | CN | disclosed |
| US-20090258921-A1 | INDOLE DERIVATIVES | NOMURA SUMIHIRO | 2009-10-15 | — | — | US | disclosed |
| US-20080119422-A1 | Indole Derivatives | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2008-05-22 | — | — | US | disclosed |
| CN-101111492-A | Indole derivatives | TANABE SEIYAKU CO (JP) | 2008-01-23 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090258921-A1 | INDOLE DERIVATIVES | IDO1, TPH1, NAT1 | TSHR 62/4885KDM4E 2208/4885LMNA 4770/4885 |
| US-20080119422-A1 | Indole Derivatives | IDO1, TPH1, NAT1 | TSHR 62/4885KDM4E 2208/4885LMNA 4770/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.